Weiss Asset Management’s ADMA Biologics ADMA Stock Holding History

Weiss Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-17,381	Closed	-$42K	–	306
2018 Q4	$42K	Buy	+17,381	New	+$86.1K	﹤0.01%	441

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

MWVC

Morgens Waterfall Vintiadis & Co New York $131M AUM 101.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Weiss Asset Management's ADMA Position: Q1 2019 in Review

Weiss Asset Management sold out of ADMA Biologics (ADMA) in Q1 2019, closing a stake of 17,381 shares — an estimated $42K sold.

Weiss Asset Management first reported a position in ADMA in Q4 2018 and held it in 1 quarter. The position peaked at $42K in Q4 2018. 56 funds tracked by Wall St. Rank hold ADMA as of Q1 2019.

Weiss Asset Management reported no remaining ADMA Biologics position as of Q1 2019 after selling out during the quarter.
Weiss Asset Management sold 17,381 ADMA Biologics shares in Q1 2019, an estimated $42K.
Weiss Asset Management first reported a position in ADMA Biologics in Q4 2018 and held it in 1 quarter.
Weiss Asset Management's ADMA Biologics position peaked at $42K in Q4 2018.
56 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2019.

Based on Weiss Asset Management's 13F filing for Q1 2019, filed 15 May 2019.